Effects of the 5-HT6receptor antagonist idalopirdine on extracellular levels of monoamines, glutamate and acetylcholine in the rat medial prefrontal cortex

European Journal of Pharmacology

Volumn 799, Issue , 2017, Pages 1-6

  Mørk, Arne ^a   Russell, Rasmus Vinther ^a   de Jong, Inge E M ^a   Smagin, Gennady ^b  

^a H LUNDBECK A S   (Denmark)

^b LUNDBECK RESEARCH USA   (United States)

Author keywords

Alzheimer's disease; Donepezil; Idalopirdine; Serotonin 5 HT6receptor

Indexed keywords

ACETYLCHOLINE; DONEPEZIL; DOPAMINE; GLUTAMIC ACID; IDALOPIRDINE; MONOAMINE; NORADRENALIN; SEROTONIN; SEROTONIN 6 RECEPTOR; (2-(6-FLUORO-1H-INDOL-3-YL)-ETHYL)-(3-(2,2,3,3-TETRAFLUOROPROPOXY)BENZYL)AMINE; BENZYLAMINE DERIVATIVE; BIOGENIC AMINE; INDOLE DERIVATIVE; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN REGION; BRAIN SIZE; CELL LEVEL; COGNITION; CONTROLLED STUDY; DORSAL HIPPOCAMPUS; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; IN VIVO STUDY; MALE; MEDIAL PREFRONTAL CORTEX; MICRODIALYSIS; NONHUMAN; PROTEIN DETERMINATION; PROTEIN FUNCTION; RAT; ANIMAL; CYTOLOGY; DRUG EFFECTS; EXTRACELLULAR SPACE; METABOLISM; PREFRONTAL CORTEX; SPRAGUE DAWLEY RAT;

ACETYLCHOLINE; ANIMALS; BENZYLAMINES; BIOGENIC MONOAMINES; EXTRACELLULAR SPACE; GLUTAMIC ACID; INDOLES; MALE; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS;

EID: 85012072372     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2017.02.010     Document Type: Article

References (53)

1. Allgaier, M., Allgaier, C., An update on drug treatment options of Alzheimer's disease. Front. Biosci. 19 (2014), 1345–1354.
2. Arnt, J., Bang-Andersen, B., Grayson, B., Bymaster, F.P., Cohen, M.P., DeLapp, N.W., Giethlen, B., Kreilgaard, M., McKinzie, D.L., Neill, J.C., Nelson, D.L., Nielsen, S.M., Poulsen, M.N., Schaus, J.M., Witten, L.M., Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int. J. Neuropsychopharmacol. 13 (2010), 1021–1033.
3. Asaoka, N., Nagayasu, K., Nishitani, N., Yamashiro, M., Shirakawa, H., Nakagawa, T., Kaneko, S., Olanzapine augments the effect of selective serotonin reuptake inhibitors by suppressing GABAergic inhibition via antagonism of 5-HT(6) receptors in the dorsal raphe nucleus. Neuropharmacology 95 (2015), 261–268.
4. Bali, A., Singh, S., Serotonergic 5-HT6 receptor antagonists: heterocyclic chemistry and potential therapeutic significance. Curr. Top. Med. Chem. 15 (2015), 1643–1662.
5. Benhamu, B., Martin-Fontecha, M., Vazquez-Villa, H., Pardo, L., Lopez-Rodriguez, M.L., Serotonin 5-HT6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer's disease. J. Med. Chem. 57 (2014), 7160–7181.
6. Bourson, A., Borroni, E., Austin, R.H., Monsma, F.J. Jr., Sleight, A.J., Determination of the role of the 5-ht6 receptor in the rat brain: a study using antisense oligonucleotides. J. Pharmacol. Exp. Ther. 274 (1995), 173–180.
7. Campos, C., Rocha, N.B., Vieira, R.T., Rocha, S.A., Telles-Correia, D., Paes, F., Yuan, T., Nardi, A.E., Arias-Carrion, O., Machado, S., Caixeta, L., Treatment of cognitive deficits in Alzheimer's disease: a psychopharmacological review. Psychiatr. Danub. 28 (2016), 2–12.
8. Cross, A.J., Crow, T.J., Johnson, J.A., Joseph, M.H., Perry, E.K., Perry, R.H., Blessed, G., Tomlinson, B.E., Monoamine metabolism in senile dementia of Alzheimer type. J. Neurol. Sci. 60 (1983), 383–392.
9. Da Silva Costa-Aze, V., Quiedeville, A., Boulouard, M., Dauphin, F., 5-HT6 receptor blockade differentially affects scopolamine-induced deficits of working memory, recognition memory and aversive learning in mice. Psychopharmacology 222 (2012), 99–115.
10. Dale, E., Zhang, H., Leiser, S.C., Xiao, Y., Lu, D., Yang, C.R., Plath, N., Sanchez, C., Vortioxetine disinhibits pyramidal cell function and enhances synaptic plasticity in the rat hippocampus. J. Psychopharmacol. 28 (2014), 891–902.
11. Dawson, L.A., The central role of 5-HT6 receptors in modulating brain neurochemistry. Int. Rev. Neurobiol. 96 (2011), 1–26.
12. Dawson, L.A., Nguyen, H.Q., Li, P., The 5-HT(6) receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus. Neuropsychopharmacology 25 (2001), 662–668.
13. de Bruin, N.M., Prickaerts, J., van, L.A., Venhorst, J., De, G.L., Houba, P., Reneerkens, O., Akkerman, S., Kruse, C.G., Two novel 5-HT6 receptor antagonists ameliorate scopolamine-induced memory deficits in the object recognition and object location tasks in Wistar rats. Neurobiol. Learn. Mem. 96 (2011), 392–402.
14. Deardorff, W.J., Feen, E., Grossberg, G.T., The use of cholinesterase inhibitors across all stages of Alzheimer's disease. Drugs Aging 32 (2015), 537–547.
15. Ferreira-Vieira, T.H., Guimaraes, I.M., Silva, F.R., Ribeiro, F.M., Alzheimer's disease: targeting the cholinergic system. Curr. Neuropharmacol. 14 (2016), 101–115.
16. Fone, K.C., An update on the role of the 5-hydroxytryptamine6 receptor in cognitive function. Neuropharmacology 55 (2008), 1015–1022.
17. Gerard, C., el, M.S., Lebrand, C., Adrien, J., Ruat, M., Traiffort, E., Hamon, M., Martres, M.P., Quantitative RT-PCR distribution of serotonin 5-HT6 receptor mRNA in the central nervous system of control or 5,7-dihydroxytryptamine-treated rats. Synapse 23 (1996), 164–173.
18. Helboe, L., Egebjerg, J., de Jong, I.E., Distribution of serotonin receptor 5-HT6 mRNA in rat neuronal subpopulations: a double in situ hybridization study. Neuroscience 310 (2015), 442–454.
19. Herrik, K.F., Mørk, A., Richard, N., Bundgaard, C., Bastlund, J.F., de Jong, I.E., The 5-HT receptor antagonist idalopirdine potentiates the effects of acetylcholinesterase inhibition on neuronal network oscillations and extracellular acetylcholine levels in the rat dorsal hippocampus. Neuropharmacology 107 (2016), 351–363.
20. Hirst, W.D., Stean, T.O., Rogers, D.C., Sunter, D., Pugh, P., Moss, S.F., Bromidge, S.M., Riley, G., Smith, D.R., Bartlett, S., Heidbreder, C.A., Atkins, A.R., Lacroix, L.P., Dawson, L.A., Foley, A.G., Regan, C.M., Upton, N., SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. Eur. J. Pharmacol. 553 (2006), 109–119.
21. Hovelsø, N., Karlsson, J.J., Arnt, J., Mørk, A., 2010. The 5-HT6 receptor antagonist, Lu AE58054 blocks the effect of 5-HT6 receptor-stimulated modulation of neurotransmitter levels in the prefrontal cortex and potentiates the effect of donepezil on hippocampal theta power. In: Proceedings of the 40th Annual Meeting of the Society of Neuroscience.
22. Ivachtchenko, A.V., Lavrovsky, Y., Ivanenkov, Y.A., AVN-211, novel and highly selective 5-HT6 receptor small molecule antagonist, for the treatment of Alzheimer's disease. Mol. Pharm. 13 (2016), 945–963.
23. Jongkees, B.J., Hommel, B., Kuhn, S., Colzato, L.S., Effect of tyrosine supplementation on clinical and healthy populations under stress or cognitive demands—A review. J. Psychiatr. Res. 70 (2015), 50–57.
24. Kim, H.J., Moon, W.J., Han, S.H., Differential cholinergic pathway involvement in Alzheimer's disease and subcortical ischemic vascular dementia. J. Alzheimers Dis. 35 (2013), 129–136.
25. Kobayashi, H., Ohnishi, T., Nakagawa, R., Yoshizawa, K., The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease: a Bayesian network meta-analysis. Int. J. Geriatr. Psychiatry, 2015.
26. Lacroix, L.P., Dawson, L.A., Hagan, J.J., Heidbreder, C.A., 5-HT6 receptor antagonist SB-271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex. Synapse 51 (2004), 158–164.
27. Marcos, B., Chuang, T.T., Gil-Bea, F.J., Ramirez, M.J., Effects of 5-HT6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat. Br. J. Pharmacol. 155 (2008), 434–440.
28. Marcos, B., Gil-Bea, F.J., Hirst, W.D., Garcia-Alloza, M., Ramirez, M.J., Lack of localization of 5-HT6 receptors on cholinergic neurons: implication of multiple neurotransmitter systems in 5-HT6 receptor-mediated acetylcholine release. Eur. J. Neurosci. 24 (2006), 1299–1306.
29. Meneses, A., 5-HT systems: emergent targets for memory formation and memory alterations. Rev. Neurosci. 24 (2013), 629–664.
30. Mitchell, E.S., Sexton, T., Neumaier, J.F., Increased expression of 5-HT6 receptors in the rat dorsomedial striatum impairs instrumental learning. Neuropsychopharmacology 32 (2007), 1520–1530.
31. Mohler, E.G., Baker, P.M., Gannon, K.S., Jones, S.S., Shacham, S., Sweeney, J.A., Ragozzino, M.E., The effects of PRX-07034, a novel 5-HT6 antagonist, on cognitive flexibility and working memory in rats. Psychopharmacology 220 (2012), 687–696.
32. Mørk, A., Witten, L.M., Arnt, J., Effect of sertindole on extracellular dopamine, acetylcholine, and glutamate in the medial prefrontal cortex of conscious rats: a comparison with risperidone and exploration of mechanisms involved. Psychopharmacology 206 (2009), 39–49.
33. Parker, C.A., Gunn, R.N., Rabiner, E.A., Slifstein, M., Comley, R., Salinas, C., Johnson, C.N., Jakobsen, S., Houle, S., Laruelle, M., Cunningham, V.J., Martarello, L., Radiosynthesis and characterization of 11C-GSK215083 as a PET radioligand for the 5-HT6 receptor. J. Nucl. Med. 53 (2012), 295–303.
34. Paxinos, G., Watson, C., The Rat Brain in Sterotaxic Coordinates. 1998, Academic Press, San Diego.
35. Raina, P., Santaguida, P., Ismaila, A., Patterson, C., Cowan, D., Levine, M., Booker, L., Oremus, M., Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann. Intern. Med. 148 (2008), 379–397.
36. Riemer, C., Borroni, E., Levet-Trafit, B., Martin, J.R., Poli, S., Porter, R.H., Bos, M., Influence of the 5-HT6 receptor on acetylcholine release in the cortex: pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine, a potent and selective 5-HT6 receptor antagonist. J. Med. Chem. 46 (2003), 1273–1276.
37. Riga, M.S., Sanchez, C., Celada, P., Artigas, F., Involvement of 5-HT3 receptors in the action of vortioxetine in rat brain: focus on glutamatergic and GABAergic neurotransmission. Neuropharmacology 108 (2016), 73–81.
38. Scarpini, E., Scheltens, P., Feldman, H., Treatment of Alzheimer's disease: current status and new perspectives. Lancet Neurol. 2 (2003), 539–547.
39. Schechter, L.E., Lin, Q., Smith, D.L., Zhang, G., Shan, Q., Platt, B., Brandt, M.R., Dawson, L.A., Cole, D., Bernotas, R., Robichaud, A., Rosenzweig-Lipson, S., Beyer, C.E., Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466. Neuropsychopharmacology 33 (2008), 1323–1335.
40. Shukla, R., Watakabe, A., Yamamori, T., mRNA expression profile of serotonin receptor subtypes and distribution of serotonergic terminations in marmoset brain. Front. Neural Circuits, 8, 2014, 52.
41. Spencer, R.C., Devilbiss, D.M., Berridge, C.W., The cognition-enhancing effects of psychostimulants involve direct action in the prefrontal cortex. Biol. Psychiatry 77 (2015), 940–950.
42. Tan, C.C., Yu, J.T., Wang, H.F., Tan, M.S., Meng, X.F., Wang, C., Jiang, T., Zhu, X.C., Tan, L., Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. J. Alzheimers Dis. 41 (2014), 615–631.
43. Upton, N., Chuang, T.T., Hunter, A.J., Virley, D.J., 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease. Neurotherapeutics 5 (2008), 458–469.
44. Vandesquille, M., Carrie, I., Louis, C., Beracochea, D., Lestage, P., Effects of positive modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors in a benzodiazepine-induced deficit of spatial discrimination in mice. J. Psychopharmacol. 26 (2012), 845–856.
45. Vijayraghavan, S., Wang, M., Birnbaum, S.G., Williams, G.V., Arnsten, A.F., Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory. Nat. Neurosci. 10 (2007), 376–384.
46. Wang, H.Y., Lu, C.W., Lin, T.Y., Kuo, J.R., Wang, S.J., WAY208466 inhibits glutamate release at hippocampal nerve terminals. Eur. J. Pharmacol. 781 (2016), 117–127.
47. West, P.J., Marcy, V.R., Marino, M.J., Schaffhauser, H., Activation of the 5-HT(6) receptor attenuates long-term potentiation and facilitates GABAergic neurotransmission in rat hippocampus. Neuroscience 164 (2009), 692–701.
48. Westbrook, A., Braver, T.S., Dopamine does double duty in motivating cognitive effort. Neuron 89 (2016), 695–710.
49. Wicke, K., Haupt, A., Bespalov, A., Investigational drugs targeting 5-HT6 receptors for the treatment of Alzheimer's disease. Expert Opin. Investig. Drugs 24 (2015), 1515–1528.
50. Wilkinson, D., Windfeld, K., Colding-Jorgensen, E., Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 13 (2014), 1092–1099.
51. Woolley, M.L., Bentley, J.C., Sleight, A.J., Marsden, C.A., Fone, K.C., A role for 5-ht6 receptors in retention of spatial learning in the Morris water maze. Neuropharmacology 41 (2001), 210–219.
52. Woolley, M.L., Marsden, C.A., Fone, K.C., 5-ht6 receptors. Curr. Drug Targets CNS Neurol. Disord. 3 (2004), 59–79.
53. Wu, H.Q., Pereira, E.F., Bruno, J.P., Pellicciari, R., Albuquerque, E.X., Schwarcz, R., The astrocyte-derived alpha7 nicotinic receptor antagonist kynurenic acid controls extracellular glutamate levels in the prefrontal cortex. J. Mol. Neurosci. 40 (2010), 204–210.